# An Insulin Sensitivity Study in Healthy Subjects

> **NCT02922426** · PHASE1 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** ALKS 3831
- **DRUG:** Olanzapine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02922426
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-07-20
- **Final completion:** 2017-07-20
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02922426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02922426, "An Insulin Sensitivity Study in Healthy Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02922426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*